ALZN Alzamend Neuro, Inc. Insider Trading

Director Milton C Ault III buys 108,388 shares of ALZN at $1.00; stock down 85.9% from 52-week high, company unprofitable.

Director Milton C Ault III purchased 108,388 shares at $1.00, increasing his holdings from 8,260 shares to 116,648 shares (a 1312.2% increase). The buy occurred in a deeply depressed price environment: the stock trades at $1.00, down 85.9% from its 52-week high of $7.10 and down 46.2% over the preceding 30 days. Alzamend Neuro is an unprofitable micro-cap with a market cap of $3.8M and a full-year net income of $-2.2M, limiting the informational value of insider buying as a positive signal. While Ault's cross-ticker track record shows 20 prior buys averaging a 30-day return of +1.6%, this transaction's significance is constrained by the company's micro-cap status, ongoing losses, and the large magnitude of the price decline preceding the purchase.

ALZN Director Horne buys 3.3K shares at $0.99; stock down 89.7% from 52-week high; unprofitable company; cluster pattern with 2 other insiders buying within 14 days.

Director William B. Horne purchased 3,334 shares at $0.99 on 2025-03-26, increasing his holdings to 30,000 shares and representing a +12.5% increase in his position. The stock is currently trading at $9.90, down 89.7% from its 52-week high of $96.30, suggesting a dramatic valuation reset. Fundamentals are weak: Alzamend Neuro reported negative net income of $-1,039,434.00 over its most recent full fiscal year, and the company is unprofitable. However, the timing and clustering are notable—this is the director's third consecutive buy at ALZN within 6 days (prior buys on 2025-03-20 and 2025-03-18), and 2 other insiders also bought within the past 14 days, creating a cluster buy pattern. This repeated accumulation by multiple insiders at deeply depressed prices, despite negative fundamentals, merits close examination of whether management has information about stabilization, recapitalization, or strategic developments not yet disclosed to the market.

Director Milton Ault bought 2,905 shares of ALZN at $1.02; stock down 90.6% from 52-week high, unprofitable company, cluster pattern with 2 other insiders in 14 days.

Director Milton Ault purchased 2,905 shares at $1.02 on 2025-03-21, the third insider buy at ALZN within 14 days, suggesting coordinated accumulation at severely depressed valuations. The stock is trading at $9.09, down 90.6% from its 52-week high of $96.30 and well below the transaction price, indicating either a continued structural decline or a temporary bottoming. Fundamentally, the company reported net income of $-1,039,434.00 and a market cap of $59,971,338.63, revealing it is unprofitable and trading at distressed multiples. Ault's cross-ticker track record shows an average 90-day return of +906.9% on 20 prior buys, but his same-ticker history at ALZN comprises only 2 prior purchases (on 2025-03-18 and 2025-03-12) with outcomes not yet measurable, so the historical success rate does not yet predict outcome at this ticker.

CFO David Katzoff buys 5,000 shares of ALZN at $1.01; 5.5K post-transaction holdings, joining 2 other insiders in cluster buy.

CFO David Katzoff purchased 5,000 shares at $1.01 on 2025-03-21, increasing his holdings by 925.9% from 540 to 5,540 shares. The stock is currently trading at $9.18, down 90.5% from its 52-week high of $96.30, placing his entry point near a significant trough. His cross-ticker track record shows 1 prior buy with an average 90-day return of +41935.7%, and his prior ALZN buy on 2023-09-26 was well-timed at the 90-day mark, suggesting some pattern of accumulation at attractive inflection points. The coincident cluster activity—2 other insiders also bought within the past 14 days—indicates potential coordinated conviction, though the company is unprofitable with a negative net income of $-1,039,434.00. This large relative buy by the CFO warrants tracking to determine whether it reflects confidence in a turnaround or opportunistic accumulation at distressed pricing.

Director William B. Horne purchased 5,000 ALZN shares at $0.98 on March 20, 2025; holdings now 26.7K shares.

Director William B. Horne purchased 5,000 shares at $0.98, increasing his holdings by 23.1% to 26.7K shares. The transaction occurred while Alzamend Neuro trades at $8.80, down 90.9% from a 52-week high of $96.30 and off 9.5% over 30 days, indicating a company in significant distress. Fundamentally, the company posted a negative net income of $-1.0M in its most recent fiscal year, with a modest market cap of $58.1M, signaling ongoing unprofitability. This purchase represents only the director's second open-market buy across his entire cross-ticker history and his second transaction at ALZN within two trading days (following a March 18 purchase), but offers limited insight into conviction given the extremely small sample size and absence of prior measurable outcomes at this ticker.

Director William B. Horne buys 5,000 ALZN shares at $0.97, raising stake to 21,666 shares amid -91.1% tumble from 52-week high.

Director Horne purchased 5,000 shares at $0.97 on 2025-03-18, increasing his holdings by 30.0% from 16,666 to 21,666 shares. The transaction occurred as the stock trades at $8.56, down 91.1% from its 52-week high of $96.30, and has declined 23.9% over the past 90 days. The company reported negative net income of $-1,039,434.00 for its most recent full fiscal year. The combination of a substantial accumulated losses, pronounced price decline from peak, and a director's purchase at depressed prices relative to recent history warrants examination of whether this represents opportunistic accumulation or reflects underlying confidence in operational recovery.

Director Ault buys 5,000 ALZN shares at $0.96; stock now $8.46, down 91.2% from 52-week high of $96.30

Director Milton C Ault III purchased 5,000 shares at $0.96 on 2025-03-18, increasing his holdings from 77.4K to 82.4K shares. The purchase came six days after a prior buy at the same ticker on 2025-03-12, suggesting continued accumulation despite the stock's recent weakness. The company is unprofitable with net income of $-1.0M, and ALZN has collapsed 91.2% from its 52-week high of $96.30, down 13.8% in the past 30 days and 23.6% over 90 days. While Ault's cross-ticker track record shows an average 90-day return of +907.4% across 20 prior buys with a 50.00% win rate, his same-ticker history at ALZN contains only one measurable prior trade, and outcomes for both the March 12 and March 18 purchases remain too recent to evaluate. The concentrated timing of two purchases within six days during a period of severe drawdown warrants observation of whether subsequent price action validates or undermines this activity.

Director Milton Ault III bought 100 ALZN shares at $0.68; stock now $6.09, down 94.4% from 52-week high of $108.00

Milton Ault III, a Director, acquired 100 shares of Alzamend Neuro at $0.68 on 2025-03-12, bringing his holdings to 77,368 shares. The purchase follows a severe drawdown: the stock has fallen -94.4% from its 52-week high of $108.00 and declined -37.9% over the past 30 days and -43.1% over 90 days. While the insider's cross-ticker track record shows 20 prior buys with strong average returns (+914.3% at 30 days, +980.7% at 90 days, 61.54% win rate), the company itself remains unprofitable with net income of $-1,039,434.00 over the most recent full fiscal year. The modest transaction size of $68.42 does not constitute a material commitment relative to his existing stake, limiting inference about conviction; the interaction between a strong historical track record and the company's fundamental weakness merits monitoring to understand whether this purchase reflects selective opportunity recognition or execution of a broader portfolio plan.

Director Milton Ault buys 75 ALZN shares at $2.75; stock down 96.5% from 52-week high, unprofitable company, prior 4 trades at ALZN all well-timed

Director Milton C Ault purchased 75 shares of Alzamend Neuro at $2.75 on 2024-08-06, adding to a position of 77.2K shares. The timing is notable because Ault's prior four purchases at ALZN (on 2024-01-05, 2024-04-01, 2024-04-19, and 2024-07-31) were all well-timed at the 90-day mark, with returns ranging from +4882.7% to +7852.9%. The current price of $18.18 is 96.5% below the 52-week high of $521.91, and the company is unprofitable with net income of $-2.7M and market cap of $15.3M. This latest buy continues a pattern of purchases by Ault during periods of significant price declines, consistent with his observed historical behavior at this ticker.

Director Milton Ault buys 25 ALZN shares at $3.74; stock now $31.64, down -95.0% from 52-week high $639.22 after -51.6% 90-day decline.

Director Ault purchased 25 shares of Alzamend Neuro on 2024-07-31 at $3.74, a modest position increase to 77,193 shares. This buy occurs amid severe price deterioration: the stock trades at $31.64, representing a -95.0% decline from its 52-week high of $639.22 and a -51.6% drop over the past 90 days. Notably, Ault's prior 5 buys at ALZN have demonstrated exceptional timing, with each achieving positive 90-day returns ranging from +4882.7% to +10000.0%, and all 5 trades being well-timed at the 90-day mark. However, the company's fundamentals present a critical constraint: Alzamend reported a net loss of $-2,662,418.00 over its most recent fiscal year with a modest market cap of $26,616,833.60. The current purchase at a depressed price point mirrors Ault's historical pattern at this ticker, but investors should weigh the directional signal against the company's ongoing unprofitability and the severe equity erosion already realized from the 52-week peak.